Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

Overview

cited authors

Mann, Johannes F. E.; Rossing, Peter; Bakris, George; Belmar, Nicolas; Bosch-Traberg, Heidrun; Busch, Robert; Charytan, David M.; Hadjadj, Samy; Gillard, Pieter; Gorriz, Jose Luis; Idorn, Thomas; Ji, Linong; Mahaffey, Kenneth W.; Perkovic, Vlado; Rasmussen, Soren; Schmieder, Roland E.; Pratley, Richard E.; Tuttle, Katherine R.

Publication Date

June 24, 2024

webpage

Web of Science

published in

NATURE MEDICINE Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.